期刊
CELL
卷 155, 期 7, 页码 1451-1463出版社
CELL PRESS
DOI: 10.1016/j.cell.2013.11.024
关键词
-
资金
- Caltech Innovation Fellowship
- Autism Speaks Weatherstone Fellowship
- NIH/NRSA Predoctoral Fellowship
- Human Frontiers Science Program Fellowship
- DOD Graduate Fellowship
- NSF Graduate Research Fellowship
- Autism Speaks Trailblazer Award
- Caltech Innovation Initiative
- Caltech Grubstake Awards
- Congressionally Directed Medical Research Award
- Weston Havens Award
- Callie D. McGrath Charitable Foundation
- NIMH [MH100556]
Neurodevelopmental disorders, including autism spectrum disorder (ASD), are defined by core behavioral impairments; however, subsets of individuals display a spectrum of gastrointestinal (GI) abnormalities. We demonstrate GI barrier defects and microbiota alterations in the maternal immune activation (MIA) mouse model that is known to display features of ASD. Oral treatment of MIA offspring with the human commensal Bacteroides fragilis corrects gut permeability, alters microbial composition, and ameliorates defects in communicative, stereotypic, anxiety-like and sensorimotor behaviors. MIA offspring display an altered serum metabolomic profile, and B. fragilis modulates levels of several metabolites. Treating naive mice with a metabolite that is increased by MIA and restored by B. fragilis causes certain behavioral abnormalities, suggesting that gut bacterial effects on the host metabolome impact behavior. Taken together, these findings support a gut-microbiome-brain connection in a mouse model of ASD and identify a potential probiotic therapy for GI and particular behavioral symptoms in human neurodevelopmental disorders.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据